Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights
- Design
- Narrative review · None outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: the review covers GLP-1 drug use for type 2 diabetes and obesity, conditions the target group does not have.
- Could weight loss explain it?
- PossiblyNo weight or glycaemic data are reported; the review attributes some oral effects to dehydration after gastrointestinal effects and some facial changes to rapid weight loss, without separating mechanisms.
- Study tier
- Not ratedNOT_RATED: narrative short communication with no new primary outcome data.
- Assessment
- Version 2 · Two independent AI reviews agreed · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This short narrative review gathers case reports, adverse-event reporting findings and indirect experimental evidence on mouth and saliva problems with GLP-1 drugs and tirzepatide. Reported problems include dry mouth, reduced saliva, altered taste and mouth or throat discomfort; a direct link to dental erosion has not been established. The authors say the evidence is limited and largely indirect, so how often these effects occur and whether the drugs cause them is not known.
01Findings
What the study reported
- Drugs
- Glp-1 receptor agonists, Tirzepatide
- Dose
- various
- Route
- various
- Comparator
- not reported in abstract
- Primary outcome
- oral and salivary adverse effects reported with GLP-1 receptor agonists and tirzepatide
- Effect
- No quantitative result; reported manifestations are listed (xerostomia, hyposalivation, dysgeusia and others), and a direct association with dental erosion has not been established
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Reported xerostomia, hyposalivation, dysgeusia, oral mucosal discomfort, burning sensations and throat-related symptoms; possible susceptibility to dental erosion, with no direct association established; evidence limited and largely indirect
- Limitations
- Narrative short communication drawing on case reports, pharmacovigilance and indirect experimental evidence; the authors say evidence is limited and largely indirect and that causality and frequency remain to be clarified.
Who was studied
- Obesity status
- mixed (review scope: drug use for type 2 diabetes and obesity)
- Diabetes status
- mixed (review scope: drug use for type 2 diabetes and obesity)
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes mellitus and obesity (indications for the drugs, review scope)
Study quality details
- Study design
- Narrative review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- n/a
- Comparator
- not reported in abstract
- Follow up duration
- not stated
- Outcome type
- none
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; no quantitative data
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[BACKGROUND] The expanding use of glucagon-like peptide-1 receptor agonists and the dual incretin agonist tirzepatide for Type 2 diabetes mellitus and obesity has drawn attention to potential oral and salivary adverse effects. This short communication summarizes the available evidence, discusses potential mechanisms, and highlights implications for oral medicine practice. [METHODS] A narrative synthesis of published case reports, pharmacovigilance findings, and indirect experimental evidence was undertaken to discuss reported manifestations, biological plausibility, and existing knowledge gaps. [RESULTS] Reported manifestations include xerostomia, hyposalivation, dysgeusia, oral mucosal discomfort, burning sensations, and throat-related symptoms. Proposed mechanisms include modulation of cyclic adenosine monophosphate-dependent signaling in salivary acinar cells, altered autonomic regulation of salivary secretion, and dehydration secondary to gastrointestinal adverse events. Reduced salivary protection combined with gastric acid exposure from reflux or vomiting may increase susceptibility to dental erosion, although a direct association with these therapies has not been established. Sporadic immune-mediated mucocutaneous reactions and facial soft-tissue changes associated with rapid weight loss have also been described. Evidence remains limited and largely indirect. [CONCLUSION] Potential oral and salivary adverse effects warrant clinical awareness, careful medication history-taking, assessment of salivary function, and individualized preventive care. Systematic reporting and focused clinical and experimental studies are needed to clarify causality, frequency, and underlying mechanisms.